Don't count us out yet, Novavax says

After losing out on the COVID-19 vaccine race, Novavax is hoping its experimental combo flu-COVID vaccine can help turn around its fortunes.

But it finds itself in a familiar position of playing catch-up.
Why it matters: A year after it warned about its ability to remain in business, the Maryland company is trailing Pfizer-BioNTech and Moderna in the development of a combination product that would reduce the need for multiple shots during respiratory virus season.